Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.750 +0.020 (+0.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

Where Editas Medicine Stands With Analysts ↗

September 17, 2024

Via Benzinga

Looking for Stock Bargains With Room to Run? Try This. ↗

September 11, 2024

Investing tips from Bill Mann, The Motley Fool's director of small-cap research.

Via The Motley Fool

Editas Medicine to Participate in Upcoming Investor Conferences

August 28, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 08, 2024

Via Benzinga

Unveiling 5 Analyst Insights On Editas Medicine ↗

June 18, 2024

Via Benzinga

The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts ↗

May 30, 2024

Via Benzinga

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

August 07, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

July 31, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition ↗

July 17, 2024

Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.

Via InvestorPlace

3 Profitable CRISPR Stocks Earning Analysts’ Praise ↗

July 09, 2024

Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future.

Via InvestorPlace

The 3 Best Gene Editing Stocks to Buy in July 2024 ↗

July 08, 2024

Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.

Via InvestorPlace

The Latest Analyst Ratings For Editas Medicine ↗

February 29, 2024

Via Benzinga

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich ↗

June 26, 2024

Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.

Via InvestorPlace

3 Gene Editing Stocks That Could Make Your Grandchildren Rich ↗

June 25, 2024

Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.

Via InvestorPlace

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

June 14, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

June 14, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential ↗

May 30, 2024

Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains.

Via InvestorPlace

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 14, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 10, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? ↗

May 09, 2024

The company has great potential if and when it enters the commercial stage.

Via The Motley Fool

EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Editas Medicine Announces First Quarter 2024 Results and Business Updates

May 08, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 02, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

May 01, 2024

Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

April 22, 2024

From Editas Medicine, Inc.

Via GlobeNewswire

1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. ↗

March 07, 2024

The company now has a chance to get its lead program out the door a bit sooner.

Via The Motley Fool

1 Beaten-Down Stock With 55% Upside, According to Wall Street ↗

March 04, 2024

The biotech has bounced back some in the past year.

Via The Motley Fool

Why Editas Medicine Stock Soared as Much as 42% Higher This Week ↗

March 02, 2024

The clinical-stage genome editing company dropped a couple of important announcements for shareholders.

Via The Motley Fool

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 28, 2024

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.